Replies to post #3493 on Pulmatrix Inc (PULM)

[riskon]

$65M+ cash and all this? Just waiting to erupt.

PUR1800 Data (which will validate iSPERSE) + 2.4Billion U.S. market for AECOPD

PUR3100 P1/P2 Trial Start - which will validate iSPERSE in taking a previously $800M acquired failed P3 (b/c of safety) formulation to market.

FEND - Beginning of marketing campaign & wildcards with WHO, CDC, Next Breath, and beyond - coming out party coming soon.

PUR1900 (Pulmazole) - FDA Fast Trac, QIDP Status, and partnered with India's largest inahlation company -- looking for other news ahead of 2023 here (LPAD?)

Nocion Partnership - At some point they will look to bring in iSPERSE into their formulations - which are in P2 moving to P3.

JnJ Partnership - At some point, won't be surprised to see JnJ re-enter on PUR1800 for long-term dosage of Lung Cancer.

Oxeia Partnership - Given Ted Raad just joined their BoD, and they have iSPERSE mentioned in a patent - wouldn't be surprised to see something.

iSPERSE as a Platform = $$$

$PULM